ID

40515

Descrizione

Study ID: 101468/218 Clinical Study ID: SKF-101468/218 Study Title:A Single-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre, Phase IIa Study to Determine the Pharmacokinetics and Tolerability of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Restless Legs Syndrome

Keywords

versioni (2)
  1. 29/04/20 29/04/20 -
  2. 08/05/20 08/05/20 -
Titolare del copyright

GlaxoSmithKline

Caricato su

29 aprile 2020

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Pharmacokinetics and Tolerability of Ropinirole in Patients Suffering from Restless Legs Syndrome 101468/218

Inglese

Dose Level 1, Day1 - Vital Signs Post Dose; Adverse Event

1 moduli  
Administrative
Descrizione

Administrative

Alias
UMLS CUI-1
C1320722
Patient Number
Descrizione

Patient Number

Tipo di dati

text

Alias
UMLS CUI [1]
C2348585
Centre Number
Descrizione

Centre Number

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0600091
UMLS CUI [1,2]
C0019994
Adverse Event
Descrizione

Adverse Event

Alias
UMLS CUI-1
C0877248
+2 hrs - Any Adverse Events?
Descrizione

If "Yes" record all details on an Adverse Event page at back of CRF.

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0877248
Next Day (+12hrs) by telephone - Any Adverse Events?
Descrizione

If "Yes" record all details on an Adverse Event page at back of CRF.

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0877248
In the Investigator’s opinion, is it safe for the patient to continue dosing at home?
Descrizione

Y - Ensure patient returns home with their study medication and diary card N - Select a dosing strategy from options below and tick the relevant box

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0805733
UMLS CUI [1,2]
C2603343
UMLS CUI [1,3]
C4534363
If it is not safe for the patient to continue dosing at home, select a dosing strategy from options below and tick the relevant
Descrizione

If it is not safe for the patient to continue dosing at home, select a dosing strategy from options below and tick the relevant

Tipo di dati

integer

Alias
UMLS CUI [1,1]
C0805733
UMLS CUI [1,2]
C2603343
UMLS CUI [1,3]
C4534363
UMLS CUI [2,1]
C0178602
UMLS CUI [2,2]
C0679199
Ritorna all'inizio della pagina

Similar models

Dose Level 1, Day1 - Vital Signs Post Dose; Adverse Event

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Administrative
C1320722 (UMLS CUI-1)
Patient Number
Item
Patient Number
text
C2348585 (UMLS CUI [1])
Centre Number
Item
Centre Number
text
C0600091 (UMLS CUI [1,1])
C0019994 (UMLS CUI [1,2])
Item Group
Adverse Event
C0877248 (UMLS CUI-1)
+2 hrs - Any Adverse Events?
Item
+2 hrs - Any Adverse Events?
boolean
C0877248 (UMLS CUI [1])
Next Day (+12hrs) by telephone - Any Adverse Events?
Item
Next Day (+12hrs) by telephone - Any Adverse Events?
boolean
C0877248 (UMLS CUI [1])
In the Investigator’s opinion, is it safe for the patient to continue dosing at home?
Item
In the Investigator’s opinion, is it safe for the patient to continue dosing at home?
boolean
C0805733 (UMLS CUI [1,1])
C2603343 (UMLS CUI [1,2])
C4534363 (UMLS CUI [1,3])
Item
If it is not safe for the patient to continue dosing at home, select a dosing strategy from options below and tick the relevant
integer
C0805733 (UMLS CUI [1,1])
C2603343 (UMLS CUI [1,2])
C4534363 (UMLS CUI [1,3])
C0178602 (UMLS CUI [2,1])
C0679199 (UMLS CUI [2,2])
If it is not safe for the patient to continue dosing at home, select a dosing strategy from options below and tick the relevant
Code List
If it is not safe for the patient to continue dosing at home, select a dosing strategy from options below and tick the relevant
CL Item
TRY AGAIN: Patient will receive the next days dose in the clinic. Complete an Extra Clinic Visit section of the CRF for this visit. (1)
CL Item
MTD DETERMINED: No further attempts at this dose level will be made. Complete Last Clinic Visit section in the CRF. (2)
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial